Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Hospira, Inc.
EIR
•Hospira, Inc.•January 19, 2010

Hospira, Inc. – FDA EIR, Jan 19, 2010

Record Details

An FDA inspection of Hospira, Inc.'s Rocky Mount, NC facility, conducted from January 12-19, 2010, identified significant regulatory violations primarily concerning process validation for both drug and medical device products. The inspection, conducted under Good Manufacturing Practices (21 CFR Part 211) and Quality System Regulation (21 CFR Part 820) frameworks, focused on compliance for intravascular catheters containing heparin and related solutions.

Key issues cited on the FDA Form 483 included the failure to adequately validate solution tank mixing processes for various drug products and heparin lock flush solutions. The company also lacked a statistically and scientifically sound rationale for applying its mixing validation matrix to numerous products and failed to identify critical process control parameters for heparin lock flush solutions. Additionally, critical batch records from a 2003 heparin mixing validation study were destroyed, and visible particulates observed during a validation run were not investigated. Concerns were also raised about the firm still reporting adverse events for reclassified heparin products (now considered medical devices) to the Center for Drug Evaluation and Research (CDER) instead of the Center for Devices and Radiological Health (CDRH).

In response, Hospira management initiated a high-level Exception Report to assess validation program lapses and their impact, committing to a comprehensive review as a corrective measure. They also promised a written response to the FDA 483 within 15 business days. A follow-up drug inspection was recommended to thoroughly evaluate Hospira's validation program.

Company
Hospira, Inc.
Inspection date
January 19, 2010
Product type
devices
Office
Center for Devices and Radiological Health
Person
  • Thomas R. Berry (Program Expert)
View Company Profile

ID · 6fc2dda5-a6de-4424-bcde-b0a650347cc3

Violation Codes8
21 CFR 211.110(a)21 CFR 820.3021 CFR 820.70(a)21 CFR 80321 CFR 820.75(a)21 CFR 211.110(b)21 CFR 820.100(a)(6)21 CFR 800-1299

Full citation text and observation details available on the Dashboard.

Other documents for Hospira, Inc.
  • 483 - 2023-11-14November 14, 2023
  • 483 - 2019-11-21November 21, 2019
  • 483 - 2018-02-02February 2, 2018
  • WARNING_LETTER - 2013-11-15November 15, 2013
  • 483 - 2013-03-01March 1, 2013

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hospira, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.